Betagistin

General characteristics. Structure:

Active ingredient: 8 mg, 16 mg or 24 mg of a betagistin of dihydrochloride.

Excipients: cellulose microcrystallic, lactose monohydrate, кроссповидон, magnesium stearate, povidone, silicon dioxide colloid (aerosil).

Pharmacological properties:

Pharmacodynamics. Agonist of H1-histamine receptors of vessels of an inner ear and antagonist of Nz-gistaminovykh of receptors of vestibular nuclei of TsNS. Due to relaxation of precapillary sphincters of vessels of an inner ear improves blood circulation in a vascular stripe of an inner ear.

Dozozavisimo reduces generation of action potentials in neurons of lateral and medial vestibular nuclei.

Accelerates recovery of vestibular function after a unilateral vestibular neurectomy, accelerating and facilitating the central vestibular compensation (due to antagonism with Nz-gistaminovymi receptors).

Facilitates symptomatology at Menyer's syndrome and vestibular dizziness. The stable therapeutic effect occurs in 14 days.

Pharmacokinetics. Communication with proteins of plasma — less than 5% is absorbed quickly. The maximum concentration in a blood plasma in 3 hours. An elimination half-life in 3-4 hours.

It is metabolized to inactive metabolites: 2-pyridylacetic acid (main metabolite) and dimetilbetagistina. 85-90% are removed by kidneys in the form of 2-pyridylacetic acid during 24 h. Removal of a betagistin and dimetilbetagistin kidneys slightly. Intestines remove only a small part of a betagistin and it, metabolites.

Indications to use:

• Treatment of a syndrome of Menyer who is characterized by dizziness (followed by nausea and vomiting), decrease in hearing and a sonitus.
• Symptomatic treatment of vestibular dizziness (вертиго).

Route of administration and doses:

Drug is appointed inside, during food,
To adult and elderly patients: tablets of 8 mg: 1 — 2 tablets 3 times a day; tablets of 16 mg: 1/2-1 tablet 3 times a day; tablets of 24 mg: on 1 tablet 2 times a day.

Improvement is usually noted already at the beginning of therapy, the stable therapeutic effect occurs after two weeks of treatment and can increase within several months of treatment. Prolonged treatment. Duration of administration of drug is selected individually.

For patients with a renal and/or liver failure there are no changes of therapeutic dosages given about need.

Features of use:

Use at pregnancy and during breastfeeding. There are not enough data for assessment of influence of drug during pregnancy and a lactation. In this regard reception at pregnancy is not recommended. For the period of treatment it is necessary to stop breastfeeding.

The therapeutic effect in some cases increases within several months from an initiation of treatment.

Betagistin does not possess sedation and does not influence ability to driving of motor transport or in work with mechanisms.

Side effects:

Nausea, vomiting, dyspepsia, abdominal pain, abdominal distention, small tortoiseshell, itch, rash, Quincke's disease, headache.

Interaction with other medicines:

Blockers of histamine receptors reduce effect of a betagistin.

Contraindications:

Hypersensitivity, pregnancy, lactation period, children's age. Deficit of lactase, lactose intolerance, glucose-galaktoznaya malabsorption. Pheochromocytoma.

With care. A peptic ulcer of a stomach or 12 — a perstny gut (in the anamnesis), bronchial asthma. The specified patients should be observed regularly during treatment.

Overdose:

Symptoms: nausea, vomiting, headache, dermahemia of the person, dizziness, tachycardia, decrease in the ABP, bronchospasm; drowsiness (at reception in a dose to 640 mg); at a dose of 728 mg there were messages on emergence of spasms.

Treatment: gastric lavage, reception of absorbent carbon, symptomatic therapy.

Storage conditions:

In the dry, protected from light place at a temperature not above 25 °C. To store in the place, unavailable to children. Period of validity: 2 years. Not to use after a period of validity.

Issue conditions:

According to the recipe

Packaging:

Tablets of 8 mg, 16 mg and 24 mg. On 10, 12 tablets, in a blister strip packaging from a film of the polyvinyl chloride and printing aluminum foil varnished. On 1, 2 or 3 blister strip packagings together with the application instruction place in a pack. For hospitals: on 500, 1000 or 2000 tablets in banks polymeric with covers. On 1, 2, 3, 4, 5, 6 cans together with application instructions place in boxes.